Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial

Abstract Background Primary immune thrombocytopenia (ITP) is the most common acquired bleeding disorder in children, and management is challenging when first-line therapy fails. Hetrombopag is an oral thrombopoietin receptor agonist (TPO-RA). This phase 3 randomized, double-blind, placebo-controlled...

Descripció completa

Dades bibliogràfiques

Autors principals:	Runhui Wu, Ju Gao, Yufeng Liu, Jie Yu, Shaoyan Hu, Hui Liang, Hui Jiang, Xiaowen Zhai, Min Zhou, Wenge Hao, Heng Mei, Fei Li, Yumei Chen, Wei Liu, Mei Yan, Runzi Li, Junye Xiong, Zhenyi Zhu, Xiaoling Cheng, Tianyou Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-04-01
Col·lecció:	Journal of Hematology & Oncology
Matèries:	Hetrombopag Immune thrombocytopenia Children and adolescents Thrombopoietin receptor agonists Platelet response
Accés en línia:	https://doi.org/10.1186/s13045-026-01790-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!